StartBSLN • SWX
add
Basilea Pharmaceutica AG Allschwil
Seneste lukkekurs
41,15 CHF
Dagsinterval
40,60 CHF - 41,45 CHF
Årsinterval
32,00 CHF - 49,00 CHF
Markedsværdi
540,62 mio. CHF
Gns. volumen
17,18 t
P/E-værdi
47,10
Udbytteprocent
-
Primær børs
SWX
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(CHF) | dec. 2023info | År til år-ændring |
---|---|---|
Indtægt | 36,36 mio. | -19,30 % |
Driftsudgifter | 7,96 mio. | 12,34 % |
Nettoindtægt | -10,69 mio. | -187,82 % |
Overskudsgrad | -29,41 | -208,81 % |
Earnings per share | — | — |
EBITDA | -7,88 mio. | -152,08 % |
Effektiv afgiftssats | 0,08 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(CHF) | dec. 2023info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 59,93 mio. | -29,21 % |
Samlede aktiver | 173,29 mio. | -21,53 % |
Samlede passiver | 183,29 mio. | -24,12 % |
Samlet egenkapital | -10,00 mio. | — |
Shares outstanding | 12,00 mio. | — |
Kurs/indre værdi | -49,58 | — |
Afkast af aktiver | -11,81 % | — |
Afkast af kapital | -17,26 % | — |
Pengestrøm
Nettoændring i likviditet
(CHF) | dec. 2023info | År til år-ændring |
---|---|---|
Nettoindtægt | -10,69 mio. | -187,82 % |
Pengestrøm fra drift | -3,81 mio. | -210,31 % |
Pengestrøm fra investering | -322,50 t | -100,69 % |
Pengestrøm fra finansiering | -20,11 mio. | -4,52 % |
Nettoændring i likviditet | -24,31 mio. | -178,80 % |
Fri pengestrøm | -4,62 mio. | -154,24 % |
Om
Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.
The company is based in Basel, Switzerland. It has subsidiaries in France, Germany, Denmark, the People's Republic of China, Spain, the United Kingdom, and the United States of America. According to stock filings, it had 196 employees as of June 2007.
Among the company's notable products is Isavuconazole, an intravenous and oral antifungal, which received orphan drug status designation by the United States Food and Drug Administration in 2013. The company also manufactures pharmaceuticals for use against methicillin-resistant Staphylococcus aureus. Wikipedia
Administrerende direktør
Grundlagt
okt. 2000
Website
Ansatte
147